MON-LB101 Pharmacokinetics of Liothyronine during Thyroid Hormone Therapy Withdrawal

ABSTRACT: Abstract Background Liothyronine (LT3) is a substitute for levothyroxine (LT4) for thyroid cancer patients during the preparation for nuclear medicine procedures, and there is renewed interest in its use in combination with LT4 in patients who do not respond to the standard treatment. This therapy is commonly done on fixed doses potentially resulting in supraphysiologic levels of T3. A good understanding of the LT3 pharmacokinetics (PK) is necessary to design combination treatment schemes able to maintain serum T3 levels within normal range, but data on the PK of LT3 are conflicting. Here we present a study designed to characterize the PK of LT3 in patients devoid of endogenous thyroid hormone production, not receiving LT4. Methods We performed an open label PK study in patients undergoing

SUBMITTER: Celi F 

PROVIDER: S-EPMC6550962 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature